Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q5BVD1
UPID:
TTMP_HUMAN
Alternative names:
-
Alternative UPACC:
Q5BVD1; B4DNV2; B4E0Z2; Q96AJ4; Q9H5Q1
Background:
The TPA-induced transmembrane protein plays a crucial role in the LIPH-mediated synthesis of 2-acyl lysophosphatidic acid (LPA), a key lipid mediator essential for various biological processes including hair formation and growth. This protein's involvement in LPA synthesis positions it as a significant player in cellular signaling and physiological regulation.
Therapeutic significance:
Linked to Hypotrichosis 15, a condition marked by reduced hair quantity and abnormal follicles, the TPA-induced transmembrane protein's genetic variants underscore its potential as a target for therapeutic intervention. Understanding its role could open doors to novel treatments for hair growth disorders.